Literaturangaben

Zeitschrift für Infektionstherapie 6.2023

Übersicht

Sagen Sie dem Schimmel den Kampf an – Therapieoptionen bei invasiver Aspergillose und Mukormykose (S. 62)

1.     Egger M, Bellmann R, Krause R, Boyer J, Jakšić D, Hoenigl M. 2023. Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges,  Recommendations and Future Considerations. Infect Drug Resist 16:2167–2178.

2.     Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, Kern W V, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415.

3.     Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee D-G, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann A-H, Zeiher B, Ullmann AJ. 2016. Isavuconazole versus voriconazole for primary treatment of invasive mould disease  caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet (London, England) 387:760–769.

4.     Maertens JA, Rahav G, Lee D-G, Ponce-de-León A, Ramírez Sánchez IC, Klimko N, Sonet A, Haider S, Diego Vélez J, Raad I, Koh L-P, Karthaus M, Zhou J, Ben-Ami R, Motyl MR, Han S, Grandhi A, Waskin H. 2021. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis:  a phase 3, randomised, controlled, non-inferiority trial. Lancet (London, England) 397:499–509.

5.     Lestrade PPA, Meis JF, Melchers WJG, Verweij PE. 2019. Triazole resistance in Aspergillus fumigatus: recent insights and challenges for  patient management. Clin Microbiol Infect  Off Publ Eur  Soc Clin Microbiol Infect Dis 25:799–806.

6.     Boyer J, Feys S, Zsifkovits I, Hoenigl M, Egger M. 2023. Treatment of Invasive Aspergillosis: How It’s Going, Where It’s Heading. Mycopathologia 1–15.

7.     Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, Kontoyiannis DP, Raad II. 2008. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for  invasive aspergillosis in patients with hematologic malignancy. Cancer 112:1282–1287.

8.     Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst H-A, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R. 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a  randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis  an Off Publ Infect Dis  Soc Am 44:1289–1297.

9.     Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, Giagounidis A, Marchetti O, Martino R, Meert L, Paesmans M, Ameye L, Shivaprakash M, Ullmann AJ, Maertens J. 2009. An EORTC Phase II study of caspofungin as first-line therapy of invasive  aspergillosis in haematological patients. J Antimicrob Chemother 64:1274–1281.

10.     Cornely OA, Vehreschild JJ, Vehreschild MJGT, Würthwein G, Arenz D, Schwartz S, Heussel CP, Silling G, Mahne M, Franklin J, Harnischmacher U, Wilkens A, Farowski F, Karthaus M, Lehrnbecher T, Ullmann AJ, Hallek M, Groll AH. 2011. Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother 55:5798–5803.

11.     Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-León DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild MJGT, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A. 2019. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 19:e405–e421.

12.     Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Ráčil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JAH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJGT. 2016. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 16:828–837.

13.     Boyer J, Kriegl L, Krause R, Hoenigl M. 2022. Dark Mold Infections in Solid Organ Transplant Recipients. Curr Fungal Infect Rep 16:107–115.

14.     Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, Lass-Flörl C, Prattes J, Spec A, Thompson GR, Wiederhold N, Jenks JD. 2021. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs 81:1703–1729.

15.     Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold NP, Shaw KJ, Patterson TF, Filler SG, Ibrahim AS. 2020. Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine  Mucormycosis Due to Rhizopus arrhizus. Antimicrob Agents Chemother 64.

16.    Hoenigl M, Sprute R, Arastehfar A, Perfect JR, Lass-Flörl C, Bellmann R, et al. Invasive candidiasis: Investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin Investig Drugs. 2022.

Bislang mangelhaft adressiert: Infektionsprävention in Arztserien (S. 64)

1.    https://www.physics.ucla.edu/~saltzberg/

2.    Kamp MA, Slotty P, Sarikaya-Seiwert S, Steiger HJ, Hänggi D. Traumatic brain injuries in illustrated literature: experience from a series of over 700 head injuries in the Asterix comic books. Acta Neurochir (Wien) 2011; 153:1351-1355. PMID: 21472486.

3.    Wilson N, Tucker A, Heath D, Scarborough P. Licence to swill: James Bond's drinking over six decades. Med J Aust 2018; 209: 495-500. PMID: 30521444.

4.    Nielsen R, Baerheim A. Physicians in the TV soap--a study of ER. Tidsskr Nor Laegeforen 2005; 125:3464-3467. PMID: 16357895.

5.    Elkamel F. The use of television series in health education. Health Educ Res 1995; 10:225-232. PMID: 10160230.

6.    Hoffman BL, Shensa A, Wessel C, Hoffman R, Primack BA. Exposure to fictional medical television and health: a systematic review. Health Educ Res 20171; 32:107-123. PMID: 28334962.

7.    Czarny MJ, Faden RR, Nolan MT, Bodensiek E, Sugarman J. Medical and nursing students' television viewing habits: potential implications for bioethics. Am J Bioeth 2008 Dec;8(12):1-8. PMID: 19085461.

8.    Czarny MJ, Faden RR, Sugarman J. Bioethics and professionalism in popular television medical dramas. J Med Ethics 2010; 36: 203-206. PMID: 20338929.

9.    Svandra P. The ethical approach applied to the TV series ER. Rev Infirm 2013; 191:31-33. PMID: 23776983.

10.    Cambra-Badii I, Moyano E, Ortega I, Baños JE, Sentí M. TV medical dramas: health sciences students' viewing habits and potential for teaching issues related to bioethics and professionalism. BMC Med Educ 2021; 21:509. PMID: 34565375. PMCID: PMC8474903.

11.    Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17:53-80. PMID: 8789689.

12.    Ponce de León Rosales S, Hernández MV, Huertas M. Infection control in ER: how hand-washing is avoided even in fiction. Lancet Infect Dis 2005; 5:131-132. PMID: 15766643.

13.    Azap A, Erel C, Cavdar P, Deger O, Atak T, Akben T, Oztuna D. Infection control practices in TV serials: are TV stars doing right? Open Forum Infect Dis 2015; 2 (Suppl. 1):736.

14.    Carney M, King TS, Yumen A, Harnish-Cruz C, Scales R, Olympia RP. The depiction of medical errors in a sample of medical television shows. Cureus 2020; 12:e11994. PMID: 33437549. PMCID: PMC7793400.

15.    Hoffman BL, Hoffman R, Wessel CB, Shensa A, Woods MS, Primack BA. Use of fictional medical television in health sciences education: a systematic review. Adv Health Sci Educ Theory Pract 2018; 23:201-216. PMID: 28083814.

16.    Weaver R, Wilson I, Langendyk V. Medical professionalism on television: student perceptions and pedagogical implications. Health (London) 2014; 18:597-612. PMID: 24677335.

17.    Jerrentrup A, Mueller T, Glowalla U, Herder M, Henrichs N, Neubauer A, Schaefer JR. Teaching medicine with the help of “Dr. House”. PLoS One 2018; 13:e0193972. PMID: 29534114. PMCID: PMC5849285.

18.    https://www.stifterverband.org/ars-legendi-medizin

19.    https://www.imdb.com/title/tt0285403/episodes?season=5